Machine Learning

A new AI system deters birds to prevent avian flu. But its real innovation lies in data, transforming biosecurity from a costly chore into a profitable investment.

BlackRock's latest fund distributions reveal a heavy reliance on 'return of capital,' especially in its resource funds. What does this mean for investors?

Updated trial results for Lilly's Inluriyo-Verzenio combo extend life without chemo, positioning the firm for dominance in a competitive oncology market.

With FDA alignment for its pivotal Phase 3 trial, Oncolytics Biotech is poised to bring the first immunotherapy to the challenging pancreatic cancer landscape.

GrantWatch founder Libby Hikind is trading grant databases for picture books. Discover the strategy behind her pivot to value-driven children's literature.

United Imaging Intelligence's new AI agents can reason, act, and report. But are hospitals ready for the business and ethical hurdles of this new era?

Fresh off its IPO, iOThree is pushing AI and certified digital tools. Can its innovation engine and Asian expansion overcome market headwinds?

Aligos Therapeutics is using strategic stock grants to lure top talent. Is this a savvy growth play or a creeping cost for shareholders? We break it down.

Beyond the dividend payout, Cherry Hill Mortgage's strategy reveals a deeper pivot towards digital innovation, balancing high yields with new frontiers of risk.

A new AI-powered diagnostic test provides unprecedented clarity for millions at risk of esophageal cancer, challenging the old 'watch and wait' model.

Creekstone Energy plans to add 2 gigawatts of nuclear power to its Utah Gigasite, a bold move to satisfy AI's insatiable energy appetite.

Tech Mahindra's Global Chess League is partnering with AWS, using AI and smart broadcasting to transform the ancient game into a high-tech spectator sport.

Sectra posts record profits, but a costly cloud transition and security delays test its strategy. Is this the price of future leadership in AI healthcare?

New AI voice agents promise to capture millions in lost revenue for med spas by working after hours. Is this the future of the aesthetic care market?

Long Beach's new Black-Serving Institution status isn't just an equity win; it's a strategic investment in the diverse STEM talent America's defense sector needs.

An independent study shows Mesoblast’s cell therapy has superior remission rates over a market leader, hinting at a new standard of care and a big win for investors.

Serina Therapeutics poaches a top chemist to expand its POZ platform, signaling a major push beyond Parkinson's into new, high-value drug markets.

Tenaya Therapeutics seeks fresh capital to advance its heart disease pipeline, but the offering's structure raises dilution questions for investors.

A routine filing reveals a major strategic play. See how BridgeBio Oncology uses special equity grants to attract top minds in the fierce race for a cancer cure.

As TD SYNNEX prepares its full-year report, the results will be a crucial test of its AI strategy and a key indicator for the entire IT ecosystem.